Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

Summary

Prospective, single center, double-blind, randomized pharmacodynamic experimental study. The study will enroll 150 subjects with ASCVD on optimal statin therapy as per physician and Diabetes Mellitus (DM) undergoing elective Percutaneous Coronary Intervention (PCI). Eligible patients will be randomized for 30 day treatment to either 1) evolocumab 420 mg ; or 2) placebo.

Timeline

Start

2018-05-01

Primary completion

2019-09-01

Completion

2019-10-01

Drugs

Indications